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Abstract Monoamine oxidases (MAO) are important com-
ponents of the homeostatic machinery that maintains the
levels of monoamine neurotransmitters, including dopamine,
in balance. Given the imbalance in dopamine levels observed
in Huntington disease (HD), the aim of this study was to
examine MAO activity in a mouse striatal cell model of HD
and in human neural cells differentiated from control and HD
patient-derived induced pluripotent stem cell (hiPSC) lines.
We show that mouse striatal neural cells expressing mutant
huntingtin (HTT) exhibit increased MAO expression and
activity. We demonstrate using luciferase promoter assays that
the increased MAO expression reflects enhanced epigenetic
activation in striatal neural cells expressing mutant HTT.
Using cellular stress paradigms, we further demonstrate that
the increase in MAO activity in mutant striatal neural cells is
accompanied by enhanced susceptibility to oxidative stress
and impaired viability. Treatment of mutant striatal neural
cells with MAO inhibitors ameliorated oxidative stress and
improved cellular viability. Finally, we demonstrate that hu-
man HD neural cells exhibit increased MAO-A and MAO-B
expression and activity. Altogether, this study demonstrates
abnormal MAO expression and activity and suggests a poten-
tial use for MAO inhibitors in HD.
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Introduction
Huntington disease (HD) is an autosomal dominant neurode-
generative disorder that has no known cure. It is caused by an
expansion of a CAG trinucleotide repeat within exon 1 of the
huntingtin (HTT) gene, where the onset of motor symptoms
and severity of neuropathology are dependent on the size of
the trinucleotide expansion [1, 2]. The clinical profile of HD
includes motor, cognitive, and psychiatric dysfunction.
Pathologically, HD is characterized by preferential loss of
neurons in the striatum and deep layers of the cortex.
Molecular assessments during disease progression show
discrepancies in neurotransmitter levels [3, 4]. Dopamine, a
monoamine, is one such neurotransmitter. Dopamine homeo-
stasis and dopamine-regulated pathways are altered in HD
mouse models [5, 6]. In the R6/1 mouse model of HD, the
levels of striatal dopamine and its metabolite homovanillic
acid are significantly reduced [7]. Dopamine turnover is also
altered in R6/1 mice [7]. In R6/2 mice, significant deficits are
observed in extracellular and tissue levels of striatal dopamine
and in D1-class dopamine receptor signaling [5, 8–10].
Similarly, baseline and evoked extracellular levels of striatal
dopamine are reduced in YAC128 HDmice [5, 10, 11]. In pre-
symptomatic HD gene carriers, a progressive loss of dopa-
mine D1 and D2 receptor (D1R and D2R) binding is observed
by PET imaging [12–15]. Furthermore, in post mortem HD
brains, there is a reduced number of striatal D1R- and D2R-
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positive cells as assessed by messenger RNA (mRNA) detec-
tion [1, 16], and the levels of striatal dopamine are also
significantly reduced [3, 17].
One avenue of processing dopamine is through the
activity of monoamine oxidase (MAO) enzymes. MAOs
are flavin-containing enzymes located on the mitochon-
drial outer membrane which oxidatively deaminate
monoamines, generating hydrogen peroxide as a by-
product [5, 18]. Present as two isozymes, MAO-A and
MAO-B are encoded by separate genes adjacent to each
other on the short arm of the X chromosome. They also
have identical exon-intron structural organization sug-
gesting that they were derived as a result of ancestral
gene duplication [5, 18]. The two isozymes share 70 %
similarity in amino acid sequence. Dopamine is a com-
mon substrate for both isozymes but MAO-A has a
higher affinity toward serotonin, norepinephrine, and
epinephrine [5, 19, 20]. Although MAO proteins are
found throughout the brain, MAO activity varies con-
siderably from region to region, with the caudate show-
ing the highest levels of activity [12, 21].
Abnormal MAO-A and MAO-B activity has been impli-
cated in various mental and neurodegenerative disorders [16,
21], and pharmacological inhibitors of MAO have been
shown to be of clinical benefit [17, 21]. Given the marked
deficits in dopamine levels and signaling in HD, the aim of
this study was to examine MAO activity in HD patient and
rodent-derived cellular systems.
Materials and Methods
Cell Culture and Transfections
STHdhQ7/Q7 and STHdhQ111/Q111 cells were generated as de-
scribed by [18, 22]. The cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) with 10 % fetal
bovine serum (FBS; HyClone) and 5 mM glutamine (Gibco).
To transfect the cells, cells were seeded and grown until 90 %
confluency before FuGENE® 6 (Promega) was used accord-
ing to the manufacturer’s instructions. In brief, a DNA/
FuGENE ratio of 1:3 was used and the cells were incubated
with the mix over 24 h before media was changed.
Human dermal fibroblasts and HD patient-derived induced
pluripotent stem cell (hiPSC) lines from HD patients and
controls were obtained from Coriell. The sample IDs are listed
in Table 1. The dermal fibroblast cells were grown in α-MEM
(HyClone) with 10 % FBS (HyClone) and 5 mM glutamine
(Gibco). The hiPSC lines were grown as described in the
“Derivation of Neural Progenitor Cells” section.
Serum Starvation and Drug Treatment
To starve STHdhQ7/Q7 and STHdhQ111/Q111 cells of serum,
cells were seeded onto appropriate tissue culture plates and
grown until confluent. The cells were washed once with PBS
before medium without serum (DMEM with 5 mM gluta-
mine) was added. If MAO inhibitors were included into the
Table 1 Information table show-
ing Coriell cell repository IDs,




Description Gender Race Age CAG
size
ND29971 HD gene-negative (control) F Caucasian 61 20/19
ND30014 HD gene-negative (control) F Unknown 52 21/18
ND31008 HD gene-negative (control) F Unknown – 17/17
ND31845 HD gene-negative (control) F Caucasian 73 19/18
ND32603 HD gene-negative (control) F Unknown 62 19/17
ND33391 HD gene-negative (control) F Unknown – 19/17
ND30625 HD gene-negative (control) M Caucasian 76 18/17
ND31037 HD gene-negative (control) M Caucasian 30 19/17
ND30015 HD gene-positive F Unknown 28 41/21
ND30047 HD gene-positive F Caucasian 23 41/19
ND30259 HD gene-positive F Unknown 74 38/21
ND33392 HD gene-positive F Unknown 29 57/17
ND33947 HD gene-positive F Unknown 71 40/18
ND29970 HD gene-positive M Caucasian 65 40/17
ND30626 HD gene-positive M Caucasian 62 41/17
ND31551 HD gene-positive M Unknown 19 39/18
GM2183 Fibroblast line used to generate CAG33 iPSC lines F Caucasian 21 33/18
GM9197 Fibroblast line used to generate CAG180 iPSC lines M Caucasian 6 180/18
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experiment, the drugs were added upon the start of 24-h serum
starvation.
Derivation of Neural Progenitor Cells
CAG33 and CAG180 hiPSCs employed in this study
were described by the HD iPSC Consortium, 2012 [23].
Neural progenitor cells (NPCs) were derived using the
protocol described in Li et al. [24]. In brief, CAG33
and CAG180 hiPSCs at about 20 % confluence were
treated with N2B27 media (DMEM/F12: neurobasal me-
dia (1:1), 1× N2, 1× B27, 1× pen/strep/glutamine, 10 ng/
mL hLIF (Millipore), 5 μg/mL BSA) containing 3 μM
CHIR99021 (Tocris), 2 μM SB431542 (Tocris), and
0.1 μM compound E for 7 days. The culture was then
split 1:3 for the next six passages using Accutase with-
out compound E on Matrigel-coated plates.
RNA Isolation and Quantitative PCR
RNA from cells was extracted using RNeasy mini kit
(QIAGEN) according to the manufacturer’s instructions. To
generate complementary DNA (cDNA), Superscript® II
Reverse Transcription Kit (Life Technologies) was used. A
total of 20 μL of cDNAwas generated per 1 μg of RNA. To
perform quantitative PCR (qPCR), cDNAwas diluted 10-fold
and 2 μL was used per qPCR reaction. To complete the
reaction volume, 0.67 mM primers and SYBR® Select
Master Mix (Life Technologies) were added. The primers
used were as follows:
mMAO-A-F: 5′ GCCCAGTATCACAGGCCAC 3′,
mMAO-A-R: 5′ GTCCCACATAAGCTCCACCA 3′
mMAO-B-F: 5′ATGAGCAACAAAAGCGATGTGA 3′,
mMAO-B-R: 5′ TTCTAATTGTGTAAGTCCTGCCT 3′,
mActin-F: 5′ GGCTGTATTCCCCTCCATCG 3′,
mActin-F: 5′ CCAGTTGGTAACAATGCCATGT 3′,
hMAO-A-F: 5′ TTCAGGACTATCTGCTGCCAA 3′,
hMAO-A-R: 5′ GGTCCCACATAAGCTCCACC 3′,
hMAO-B-F: 5′GCTCTCTGGTTCCTGTGGTATGTG 3′,
hMAO-B-R: 5′ TCCGCTCACTCACTTGACCAGATC 3′,
hActin-F: 5′ GTCTTCCCCTCCATCGTG 3′,
hActin-R: 5′ GATGGGGTACTTCAGGGTGA 3′
hOCT4-F: 5′ TCTTTCCACCAGGCCCCCGGCTC 3′
hOCT4-R: 3′ TGCGGGCGGACATGGGGAGATCC 3′
hNESTIN-F: 5′ GAAACAGCCATAGAGGGCAAA 3′
hNESTIN-R: 5′ TGGTTTTCCAGAGTCTTCAGTGA 3′
hPAX6-F: 5′ GTGTCTACCAACCAATTCCACAAC 3′
hPAX6-R: 5′ CCCAACATGGAGCCAGATG 3′
hSOX1-F: 5′ CAGTACAGCCCCATCTCCAAC 3′
hSOX1-R: 5′ GCGGGCAAGTACATGCTGA 3′
Immunoblotting
STHdhQ7/Q7 and STHdhQ111/Q111 cells were pelleted and lysed
with homogenization buffer (50 mM Tris HCl pH 8.0,
150 mM NaCl, 1 % IGEPAL, 1 mM PMSF, 5 μM z-VAD
and 1× complete protease inhibitor cocktail (Roche)). The cell
pellets were resuspended in the homogenization buffer and
incubated on ice for 20 min. The lysates were centrifuged at
4 °C at 13,300 rpm for 15 min and the supernatant was
transferred to a new tube. The protein concentration was
measured using the Bradford Assay (Bio-Rad). Five micro-
grams of protein was used for each immunoblotting analysis.
Protein lysates were separated on a 7 % acrylamide gel and
transferred onto a nitrocellulose membrane. Blots were incu-
bated overnight at 4 °C. The antibodies used were anti-
calnexin (Sigma C4731 1:2000 dilution), anti-MAO-A
(Abcam ab126751 1:1000 dilution), anti-MAO-B (GeneTex
GTX105790 1:1000 dilution). Alexa Fluor 680 goat anti-
mouse and goat anti-rabbit (Molecular Probes) were used as
secondary antibodies (1:3000 dilution). Li-Cor Odyssey
Infrared Imaging system was used for detection and
quantification.
Luciferase Assays
To perform the luciferase assays, manufacturer’s instructions
were followed. The protocols used are briefly described
below:
Dual-Glo Luciferase Assay System
In brief, the Dual-Glo Luciferase Assay System
(Promega) was used to assay for MAO-A and MAO-B
transcriptional activity. Cells were lysed using 5× passive
lysis buffer, while shaking at room temperature for
15 min. Fifty microliters of the lysate was transferred into
an opaque 96-well plate before equal volume of Luciferin
Detection Reagent was added. After incubation at room
temperature for 20 min, the signal was measured using
FLUOstar Omega (BMG Labtech). To quench the firefly
luciferase signal, Stop and Glo buffer was added and
Renilla luciferase signal was measured.
CellTiter-Glo®
Cells were washed with PBS after drug treatment and 50 μL
of fresh media was added to each well. Equal volume of
CellTiter-Glo buffer (Promega) was added to each well and
the plate was left to shake at room temperature for 10 min
before readings were taken.
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MTTAssay
After treatment, cells in a 96-well plate were washed once with
1× PBS and incubated with 100 μL of 1 mg/mLMTT (Sigma)
in DMEM and incubated at 37 °C for 4 h. The cells were
subsequently washed with 1× PBS before adding 100 μL of
DMSO. MTT readings were taken at absorbance 570 nm.
GSH/GSSG-Glo™ Assay
Cells were washed after drug treatment and 50 μL of either
total or oxidized glutathione reagent (Promega) was added to
each well. After 5 min of shaking, equal volume of luciferin-
generation reagent was added and incubated at room temper-
ature for 30 min. Lastly, 100 μL of luciferin detection reagent
was added and luminescence was measured.
MAO-Glo Assay System
Protein lysates were diluted to 0.5 mg/mL using lysis buffer.
Twenty-five microliters of the diluted lysate was incubated with
25 μL of MAO substrate solution (1:250 dilution of provided
MAO substrate to measure MAO-B activity and 1:25 of pro-
vided MAO substrate to measure MAO-A activity) (Promega)
for 2 h at room temperature. Fifty microliters of luciferin detec-
tion reagent was then added and luminescence was measured.
ATP/ADP Measurements
To measure ATP/ADP ratios, ATP/ADP assay kit (Abcam)
was used according to the manufacturer’s instructions. In
brief, upon treatment in a 96-well plate, nucleotides were
released using 100 μL of nucleotide-releasing buffer, before
50 μL of each well was taken to measure its ATP/ADP ratio.
Immunostaining
hiPSCs and NPCs were seeded on Matrigel-coated 13 mm
coverslips in 24-well plates. Upon reaching the desired
confluency, the wells were washed with 1× PBS and fixed
with 4 % formaldehyde in PBS at room temperature for
30 min. The coverslips were washed three times for 5 min
each using wash buffer (PBS with 0.3 % Triton X-100 and
2 % goat serum) and blocked with blocking buffer (PBS with
3 % Triton X-100 and 3 % goat serum) at room temperature
for 1 h. For staining, the following antibodies and concentra-
tions were used: anti-OCT3/4 (sc-9081; Santa Cruz) 1:100;
anti-NESTIN (MAB5326; Millipore) 1:500. Antibodies were
diluted in wash buffer and incubated at 4 °C overnight. The
cells were then washed three times for 5 min each using wash
buffer and stained with secondary antibodies (Alexa Fluor,
Life Technologies) at a dilution of 1:200. After three times of
5-min washes, the cells were stained with DAPI and mounted
onto microscope slides using ProLong® Gold Antifade
Mountant (Life Technologies).
Statistical Analysis
Data are expressed as means±SEM. Statistical significance
was ascertained by one- or two-way ANOVAwith appropriate
post hoc testing or by Student’s t test. Where testing of
normality was possible, the D’Agostino and Pearson omnibus
normality test was used to assess distribution of values.
Differences were considered statistically significant when
p<0.05.
Results
MAO-A/B Activity is Elevated in STHdhQ111/Q111 Cells
To determine MAO-A/B expression patterns in a HD model,
we chose to study a set of well-characterized, immortalized
mouse striatal cell lines: the STHdhQ7/Q7 and STHdhQ111/Q111
cells. STHdhQ7/Q7 and STHdhQ111/Q111 cells were derived
from E14 striatal primordia of mice expressing 7 and 111
CAG repeats within exon 1 of the Hdh locus, respectively
[18, 25–27]. Assessment of MAO-A/B mRNA levels in the
two cell lines showed that MAO-A and MAO-B transcripts
were expressed at levels approximately fivefold higher in
STHdhQ111/Q111 than STHdhQ7/Q7 cells (unpaired two-tailed
t test; p<0.0001 for MAO-A, p=0.0052 for MAO-B)
(Fig. 1a). Consistent with the differences in transcript levels,
quantification of protein levels showed that MAO-A and
MAO-B protein levels were fourfold and twofold higher in
STHdhQ111/Q111 than STHdhQ7/Q7 cells, respectively (un-
paired two-tailed t test; p=0.0003 for MAO-A, p=0.0321
for MAO-B) (Fig. 1b).
Luciferase reporters that were previously established [17,
19, 20] were employed to examine transcriptional activities at
MAO-A and MAO-B promoter loci (Fig. 1c). Regions span-
ning 0.24 to 2 kb upstream of the MAO-A/B transcriptional
start site have been described as being critical to promote
transcription [21, 28]. We show that MAO-A/B promoter
fragments of up to 2 kb were transcriptionally active in both
STHdhQ7/Q7 and STHdhQ111/Q111 cells and, importantly, that
the transcriptional activity at the MAO-A/B promoter loci was
significantly increased in STHdhQ111/Q111 cells compared to
STHdhQ7/Q7 cells (unpaired two-tailed t test; for MAO-A
p<0.001 compared to respective STHdhQ7/Q7 controls; for
MAO-B p<0.001 for 0.24-, 0.86-, and 2-kb fragments, and
p<0.01 for 1.3-kb fragment compared to respective STHdhQ7/
Q7 controls) (Fig. 1c). To determine the functional significance
of the differences in MAO expression, MAO activity was
measured in both cell lines. In line with the expression and
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transcriptional activity reporter data, MAO-A and MAO-B
activity were elevated by approximately 1.5-fold and 2-fold
in STHdhQ111/Q111 when compared to STHdhQ7/Q7 cells, re-
spectively, (unpaired two-tailed t test; p<0.05 for MAO-A,
and p<0.001 for MAO-B) (Fig. 1d).
Stress-induced Elevation in MAO Activity Contributes
to Reduced Viability in STHdhQ111/Q111 Cells
To examine the effect of differential MAO activity in
STHdhQ7/Q7 and STHdhQ111/Q111 cells, we employed a cel-
lular stress paradigm to magnify effects induced by dispar-
ities in MAO activity. We chose the widely used serum
starvation cellular stress paradigm which has previously
been shown to increase MAO expression, and sought to
determine the effect of serum starvation in STHdhQ7/Q7 and
STHdhQ111/Q111 cells on MAO activity and cell viability [22,
29]. Serum starvation of STHdhQ7/Q7 and STHdhQ111/Q111
cells for 24 h led to increased MAO-A/B mRNA (Fig. 2a),
and in particular, in STHdhQ111/Q111 cells compared to
STHdhQ7/Q7 (two-way ANOVA; for MAO-A genotype:
F(1,33)=25.70, p<0.0001; treatment: F(1,33)=11.17, p=
0.0021; genotype × treatment: F(1,33)=9.440, p=0.0042;
for MAO-B genotype: F(1,19)=42.76, p<0.0001; treatment:
F(1,19)=11.30, p=0.0033; genotype × treatment: F(1,19)=
8.695, p=0.0084; Fisher’s least significant difference (LSD)
post hoc). Similarly, MAO-A/B protein levels were signif-
icantly higher in STHdhQ111/Q111 cells compared to
STHdhQ7/Q7 following serum starvation (Fig. 2b) (two-
way ANOVA; for MAO-A genotype: F(1,32)=54.08,
p<0.0001; treatment: F(1,32)=10.15, p=0.0032; geno-
type × treatment: F(1,32)=5.210, p=0.0292; for MAO-B
genotype: F(1,26)=11.97, p<0.0019; treatment: F(1,26)=
8.032, p=0.0088; genotype × treatment: F(1,26)=4.644,
p=0.0406; Fisher’s LSD post hoc). From an epigenetic
perspective, MAO-A/B promoter regions (2 kb fragment)
were more transcriptionally active upon serum depriva-
tion, with significantly higher transcriptional activity in
STHdhQ111/Q111 compared to STHdhQ7/Q7 cells (Fig. 2c)
(two-way ANOVA; for MAO-A genotype: F(1,8)=126.6,
p<0.0001; treatment: F(1,8)=164.4, p<0.0001; genotype
× treatment: F(1,8)=22.93, p=0.0014; for MAO-B geno-
type: F(1,8)=208.7, p<0.0001; treatment: F(1,8)=275.0,
p<0.0001; genotype × treatment: F(1,8)=21.60, p=
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Fig. 1 STHdhQ111/Q111 cells exhibit increasedMAO-A/B expression and
activity when compared to STHdhQ7/Q7 cells. a Quantitative RT-PCR
shows increased MAO-A and MAO-B expression in STHdhQ111/Q111
cells when compared to STHdhQ7/Q7 cells. Values shown were normal-
ized to STHdhQ7/Q7 cells; n=8; b A representative Western blot (left)
showing increased MAO-A and MAO-B expression in STHdhQ111/Q111
cells when compared to STHdhQ7/Q7 cells. (right) Quantification and
normalization of the band intensities demonstrate that MAO-A and
MAO-B are expressed to a greater extent in STHdhQ111/Q111 cells than
STHdhQ7/Q7 cells. Values shown were normalized to STHdhQ7/Q7 cells;
n=9. c Transcriptional activities at MAO-A and MAO-B promoter re-
gions are elevated in STHdhQ111/Q111 cells compared to STHdhQ7/Q7
cells. STHdhQ111/Q111 cells exhibited increased luciferase activity across
all promoter lengths, suggesting that transcriptional activity at MAO-A
and MAO-B promoter regions are elevated in STHdhQ111/Q111 cells,
compared to STHdhQ7/Q7 cells; n=3. ***p<0.001 when compared to
all the respective controls. dMAO-A and MAO-B activities are elevated
in STHdhQ111/Q111 cells. MAO-A and MAO-B activities were measured
using MAO-Glo™ Assay System (Promega). STHdhQ111/Q111 cells
displayed higher activity when compared to STHdhQ7/Q7 cells; n=9.
Error bars in the bar chart represent standard error of the mean, whereas
the whiskers on the box plots represent minimum and maximum values.
Q7 and Q111 refer to STHdhQ7/Q7 and STHdhQ111/Q111 cells, respectively.
a–d *p<0.05; **p<0.01; ***p<0.001 by unpaired two-tailed t test
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0.0016; Fisher’s LSD post hoc). Similar results were
obtained with the shorter MAO-A/B promoter fragments
(data not shown). Consistent with these results, MAO-A
and MAO-B activity were significantly elevated after 24 h
of serum starvation in both STHdhQ7/Q7 and STHdhQ111/
Q111 cells, but with a significantly greater increase in the
STHdhQ111/Q111 cells (Fig. 2d) (two-way ANOVA; for
MAO-A genotype: F(1,15)=15.97, p=0.0012; treatment:
F(1,15) = 5.348, p= 0.0354; genotype × treatment:
F(1,15) =0.9548, p=0.3440; for MAO-B genotype:














































































































































































Fig. 2 Serum deprivation increases MAO expression and activity in
STHdhQ111/Q111 cells. a Quantitative RT-PCR shows increased MAO-A
and MAO-B expression in STHdhQ111/Q111 cells upon serum starvation
for 24 h. Values shown were normalized to untreated STHdhQ7/Q7 cells;
n=5; (two-way ANOVA; for MAO-A genotype: F(1,33)=25.70,
p<0.0001; treatment: F(1,33)=11.17, p=0.0021; genotype × treatment:
F(1,33)=9.440, p=0.0042; for MAO-B genotype: F(1,19)=42.76,
p<0.0001; treatment: F(1,19)=11.30, p=0.0033; genotype × treatment:
F(1,19)=8.695, p=0.0084; Fisher’s LSD post hoc); b MAO-A and
MAO-B protein levels increase upon 24-h serum starvation in STHdh-
Q111/Q111 cells. Values shown were normalized to untreated STHdhQ7/Q7
cells; n=9; (two-way ANOVA; for MAO-A genotype: F(1,32)=54.08,
p<0.0001; treatment: F(1,32)=10.15, p=0.0032; genotype × treatment:
F(1,32)=5.210, p=0.0292; for MAO-B genotype: F(1,26)=11.97,
p<0.0019; treatment: F(1,26)=8.032, p=0.0088; genotype × treatment:
F(1,26)=4.644, p=0.0406; Fisher’s LSD post hoc). c Transcriptional
activity at MAO-A and MAO-B promoters increases upon serum starva-
tion. Transcriptional activity at the MAO-A and MAO-B promoter re-
gions (2-kb promoter fragment) increased upon serum starvation in
STHdhQ7/Q7 and STHdhQ111/Q111 cells; n=3; (two-way ANOVA; for
MAO-A genotype: F(1,8)=126.6, p<0.0001; treatment: F(1,8)=164.4,
p<0.0001; genotype × treatment: F(1,8)=22.93, p=0.0014; for MAO-B
genotype:F(1,8)=208.7, p<0.0001; treatment: F(1,8)=275.0, p<0.0001;
genotype × treatment: F(1,8)=21.60, p=0.0016; Fisher’s LSD post hoc)
d MAO-A and MAO-B activities are enhanced upon serum starvation.
MAO-A andMAO-B activities were measured usingMAO-Glo™Assay
System (Promega). STHdhQ7/Q7 cells and STHdhQ111/Q111 cells displayed
higher activity upon 24-h serum starvation, with the increase being
significantly greater in STHdhQ111/Q111 cells; n=11; (two-way ANOVA;
for MAO-A genotype: F(1,15)=15.97, p=0.0012; treatment: F(1,15)=
5.348, p=0.0354; genotype × treatment: F(1,15)=0.9548, p=0.3440; for
MAO-B genotype: F(1,46)=12.90, p=0.0008; treatment: F(1,46)=
14.42, p<0.0004; genotype × treatment: F(1,46)=0.1515, p=0.6989;
Fisher’s LSD post hoc). e Serum withdrawal in STHdhQ7/Q7 cells and
STHdhQ111/Q111 cells results in decreased ATP levels. ATP levels were
measured using CellTiter-Glo® upon 24-h serum starvation; n=4; (two-
way ANOVA; genotype: F(1,12)=137.4, p<0.0001; treatment: F(1,12)=
44.80, p<0.0001; genotype × treatment: F(1,12)=9.469, p=0.0096; Fish-
er’s LSD post hoc). f Serumwithdrawal results in greater reduction in cell
viability in STHdhQ111/Q111 cells as assessed by theMTTassay. STHdhQ7/
Q7 and STHdhQ111/Q111 cells were serum starved for 24 h before incuba-
tion with 1 mg/mL MTT for 4 h; n=4; (two-way ANOVA; genotype:
F(1,12)=148.5, p<0.0001; treatment: F(1,12)=44.85, p<0.0001; geno-
type × treatment: F(1,12)=6.167, p=0.0288; Fisher’s LSD post hoc).
Error bars in the bar chart represent standard error of the mean, whereas
the whiskers on the box plots represent minimum and maximum values.
Q7 and Q111 refer to STHdhQ7/Q7 and STHdhQ111/Q111 cells, respectively.
*p<0.05; **p<0.01; ***p<0.001
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F(1,46)=12.90, p=0.0008; treatment: F(1,46)=14.42,
p<0.0004; genotype × treatment: F(1,46)=0.1515, p=
0.6989; Fisher’s LSD post hoc).
Serum starvation is a widely used method to induce cell
death in many cellular systems, including the STHdhQ7/Q7 and
STHdhQ111/Q111 cells [5, 25–27]. We deprived STHdhQ7/Q7
and STHdhQ111/Q111 cells of serum over 24 h and showed that
ATP levels were reduced upon serum withdrawal (Fig. 2e),
suggesting that serum starvation led to reduced cell viability.
Interestingly, STHdhQ111/Q111 cells have inherently lower ATP
levels compared to STHdhQ7/Q7 cells. In addition, serum
starvation in STHdhQ7/Q7 cells led to a twofold reduction in
cell viability, whereas serum starvation in STHdhQ111/Q111
cells resulted in a fourfold reduction in cell viability, suggest-
ing that STHdhQ111/Q111 cells were more susceptible to serum
withdrawal-induced reduction in cell viability (Fig. 2e) (two-
way ANOVA; genotype: F(1,12)=137.4, p<0.0001; treat-
ment: F(1,12)=44.80, p<0.0001; genotype × treatment:
F(1,12)=9.469, p=0.0096; Fisher’s LSD post hoc). Similar
results were obtained with the MTT cell viability assay
(Fig. 2f) (two-way ANOVA; genotype: F(1,12)=148.5,
p<0.0001; treatment: F(1,12)=44.85, p<0.0001; genotype ×
treatment: F(1,12)=6.167, p=0.0288; Fisher’s LSD post hoc).
Reduced Viability Results from ExcessiveMAOA/BActivity
in STHdhQ111/Q111 Cells and Is Associated with Increased
Oxidative Stress
To determine if increased MAO activity plays a role in the



























































































































































































































Fig. 3 Elevated MAO-A/B activity compromises ATP metabolism and
reduces cell viability in serum-deprived STHdhQ111/Q111 cells. a MAO
inhibition rescues reduced ATP levels in serum-deprived STHdhQ111/Q111
cells. STHdhQ7/Q7 (left) and STHdhQ111/Q111 (right) cells were treated with
1μMofMAO inhibitors upon the start of serum starvation over 24 h. ATP
levels were measured using CellTiter-Glo®. Values shown were normal-
ized to no serum controls. No significant improvements were observed in
STHdhQ7/Q7 cells but inhibition of MAO in STHdhQ111/Q111 cells resulted
in an increase of ATP levels; n=12; (one-way ANOVA, p=0.0168;
individual treatment versus no serum control comparisons by one-tailed
t test). bMAO inhibition rescues serum deprivation induced cell death in
STHdhQ111/Q111 cells. STHdhQ7/Q7 (left) and STHdhQ111/Q111 (right) cells
were treated with 1 μM of MAO inhibitors upon the start of serum
starvation over 24 h before incubation with 1 mg/mLMTT for 4 h. Values
shown was normalized to no serum controls. Inhibition of MAO in
STHdhQ7/Q7 cells had no significant effect on cell death but inhibition of
MAO in STHdhQ111/Q111 cells resulted in decreased cell death; n=21;
(one-way ANOVA for STHdhQ7/Q7 p=0.6178; one-way ANOVA for
STHdhQ111/Q111 p=0.0027; individual treatment versus no serum control
comparisons by one-tailed t test). cMAO inhibition rescues reduced ATP/
ADP ratios in serum-deprived STHdhQ111/Q111 cells. STHdhQ7/Q7 (left)
and STHdhQ111/Q111 (right) cells were treated with 1 μM of MAO inhib-
itors upon the start of serum starvation over 24 h. ATP/ADP ratios were
measured using an ATP/ADP assay kit. Values shown were normalized to
no serum controls. A significant improvement was only observed in
STHdhQ111/Q111 cells where inhibition of MAO resulted in an increase
in ATP/ADP ratio; n=6; (p<0.05 by one-tailed t test); d STHdhQ111/Q111
exhibit lower ATP/ADP ratios compared to STHdhQ7/Q7 cells. ATP/ADP
ratios were measured in cells grown in normal culture conditions, in the
presence of serum. Values shown were normalized to STHdhQ7/Q7 cells;
n=3; (one-way ANOVA; for STHdhQ7/Q7 p=0.1677; for STHdhQ111/Q111
p=0.0123, Fisher’s LSD post hoc); Error bars in the bar chart represent
standard error of themean,whereas thewhiskers on the box plots represent
minimum and maximum values. Q7 and Q111 refer to STHdhQ7/Q7 and
STHdhQ111/Q111 cells, respectively. *p<0.05; **p<0.01; ***p<0.001
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upon the start of serum deprivation. Three MAO inhibitors
were used: (a) clorgyline, an irreversible MAO-A-specific
inhibitor, (b) phenelzine sulfate, an irreversible non-selective
MAO inhibitor, and (c) selegiline, an irreversible MAO-B
specific inhibitor [17, 30]. The presence of MAO inhibitors
at 1 μM led to improvements in cell viability as assessed by
CellTiter-Glo assay following serum starvation in STHdhQ111/
Q111 but not STHdhQ7/Q7 cells, suggesting that increased
MAO activity in STHdhQ111/Q111 cells contributes to the se-
rum starvation-induced reduction in cell viability (Fig. 3a)
(one-way ANOVA, p=0.0168; individual treatment versus
“no serum” control comparisons by one-tailed t test). No
improvements were observed with 0.1 or 0.01 μM of MAO
inhibitors (data not shown). As MAO activity in STHdhQ7/Q7
cells was inherently lower, inhibition of MAO activity did not
yield a significant rescue of the serum starvation-induced
reduction in cell viability in these cells. Similar results were
obtained using the MTT assay of cell viability (Fig. 3b) (one-
way ANOVA for STHdhQ7/Q7 p=0.6178; one-way ANOVA
for STHdhQ111/Q111 p=0.0027; individual treatment versus no
serum control comparisons by one-tailed t test).
The CAG tract expansion in HTT has been previously
shown to result in compromised cellular metabolism and
to lead to a reduced cellular ATP/ADP ratio [31, 32]. This
phenomenon has been observed in a number of human
and rodent HD cellular systems including HD patient
lymphoblasts, hiPSC-derived neural cells, and the
STHdhQ111/Q111 striatal cells [23, 31, 32]. Consistent with
previous studies, we observed a significantly lower ATP/
ADP ratio in STHdhQ111/Q111 compared to STHdhQ7/Q7
(Fig. 3c) (p<0.05 by one-tailed t test). To examine the
impact of MAO inhibition on this property, we measured
the ATP/ADP ratio in serum-starved STHdhQ7/Q7 and
STHdhQ111/Q111 cells at baseline and following treatment
with MAO inhibitors. While we observed no effect of
MAO inhibition on the ATP/ADP ratio in STHdhQ7/Q7
cells (Fig. 3d) (one-way ANOVA; p=0.1677), treatment
with MAO inhibitors resulted in a significant improve-
ment of the ATP/ADP ratio in STHdhQ111/Q111 cells
(Fig. 3d) (one-way ANOVA; p=0.0123; Fisher’s LSD
post hoc).
As the deamination activity of MAO isozymes triggers
oxidative reactions, we quantified oxidized (GSSG) and
reduced forms of glutathione (GSH) in both STHdhQ7/Q7
and STHdhQ111/Q111 cells upon serum starvation as a
measure of oxidative stress. We demonstrated that oxida-
tive stress increased upon the removal of serum (Fig. 4a)
(two-way ANOVA; genotype: F(1,12)=9.086, p=0.0108;
treatment: F(1,12)=26.37, p=0.0002; genotype × treat-
ment: F(1,12)=0.7452, p=0.7452; Fisher’s LSD post
hoc), reflecting a trend where both GSH/GSSG ratios
and cell viability decrease upon serum withdrawal
(Fig. 2e, f). This suggests that elevated oxidative stress
may contribute to lower cell viability. STHdhQ111/Q111
cells experienced a higher oxidative stress burden upon
serum deprivation, evident from a 3.2-fold decrease in
GSH/GSSG ratio upon serum starvation, compared to a
1.8-fold decrease in STHdhQ7/Q7 cells. This was consis-
tent with the reduction in cell viability observed in




















































































Fig. 4 Reduced viability resulting from excessive MAO-A/B activity is
associated with increased oxidative stress. a Oxidative stress increases
upon serum starvation in STHdhQ7/Q7 and STHdhQ111/Q111 cells. GSH/
GSSG levels are a surrogate measure of oxidative stress. GSH/GSSG
levels of STHdhQ7/Q7 and STHdhQ111/Q111 cells were measured in serum
and in 24-h serum-starved conditions. Values shown were normalized to
STHdhQ7/Q7 cells. Upon 24-h serum starvation, both STHdhQ7/Q7 and
STHdhQ111/Q111 cells displayed a decrease in GSH/GSSG levels. Further-
more, GSH/GSSG levels were significantly lower in STHdhQ111/Q111
compared to STHdhQ7/Q7 cells following serum starvation; n=4; (two-
way ANOVA; genotype: F(1,12)=9.086, p=0.0108; treatment: F(1,12)=
26.37, p=0.0002; genotype × treatment: F(1,12)=0.7452, p=0.7452;
Fisher’s LSD post hoc) bMAO inhibition reduces oxidative stress levels
in serum-deprived STHdhQ111/Q111 cells. GSH/GSSG levels were mea-
sured in 24-h serum-starved STHdhQ7/Q7 (left) and STHdhQ111/Q111
(right) cells in the presence of varying concentrations of MAO inhibitors.
MAO inhibitors were added upon the start of serum starvation. Values
shown were normalized to no serum controls. 1 μMof the inhibitors were
capable of increasingGSH/GSSG levels, hence, reduce oxidative stress in
STHdhQ111/Q111 cells but not STHdhQ7/Q7 cells; n=4; (individual treat-
ment versus no serum control comparisons by unpaired two-tailed t test).
The whiskers on the box plots represent minimum and maximum values.
Q7 and Q111 refer to STHdhQ7/Q7 and STHdhQ111/Q111 cells, respectively.
*p<0.05; **p<0.01; ***p<0.001
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reduction in viability in STHdhQ111/Q111 cells, compared
to a twofold reduction in STHdhQ7/Q7 cells.
To understand if MAO-A/B isozymes play a role in oxida-
tive stress, thereby influencing cell viability, we treated
STHdhQ111/Q111 and STHdhQ7/Q7 cells with MAO inhibitors
upon removal of serum and measured GSH/GSSG ratios
(Fig. 4b). Similar to cell viability measurements, the presence
of MAO inhibitors at 1 μM preferentially reduced oxidative
stress in STHdhQ111/Q111, but not STHdhQ7/Q7 cells, reinforc-
ing the notion that elevated expression and activity of MAO-
A/B in STHdhQ111/Q111 cells contributes to increased oxida-
tive stress, and thus impaired cell viability.
MAO-A/B Expression and Activity in HD Patient Fibroblasts
and hiPSC-derived Neural Cells
Of the two MAO isozymes, only MAO-A is expressed in
fibroblasts. To assess our findings from a clinical perspective,
we measured MAO-A expression and activity in eight HD
patient and eight control fibroblasts. Females and males were
represented in both the control and HD donor groups; six
control females (five HD females) and two control males
(three HD males). Taking the longer CAG polynucleotide
repeat length of the two alleles into consideration, the control
group carried an average high CAG allele length of 19±1.2
CAG repeats whereas the HD group carried an average high
CAG allele length of 42±6.1 CAG repeats. The mean ages of
the control and HD donors were 59±16.6 and 46±23.6,
respectively. Gender and age-related changes of platelet
MAO have been reported where MAO activity increases with
age [28]. Despite a lower average age of the HD donors, it is
evident that a trend presents where HD patient fibroblasts
exhibit higher levels of MAO-A expression and activity, al-
though this difference did not reach statistical significance
(Fig. 5a–b) (unpaired two-tailed t test; p=0.08 for MAO-A
mRNA and p=0.06 for MAO-A activity).
As many neuronal subtypes express both MAO-A and
MAO-B, we sought to determine whether human HD neural
cells exhibit elevatedMAO levels and activity. To this end, we
employed a well-established directed differentiation protocol
[24] to obtain human neural progenitor cells (NPCs) from
previously described HD hiPSC lines (Supplementary
Figure 1) [23]. BothMAO-A andMAO-BmRNA levels were
significantly elevated in the HD NPCs compared to control
NPCs (Fig. 5c) (unpaired two-tailed t test; p<0.001 for MAO-
A mRNA and p=0.007 for MAO-B mRNA). Similarly,
MAO-A and MAO-B activity levels were elevated in HD
























































































Fig. 5 MAO-A/B expression and activity are increased in human HD
neural cells. a Eight HD and eight control fibroblasts were analyzed for
MAO-A mRNA levels. Values shown were normalized to control fibro-
blasts. Without segregation of age and gender, HD patient fibroblasts
display a trend toward increased MAO-A expression compared to their
control counterparts; n=8; (unpaired two-tailed t test; p=0.08). b Using
MAO-Glo™ Assay System, MAO-A activities in the fibroblast lines
were tested. Compared against the control fibroblasts, HD patient fibro-
blasts exhibited a trend toward increased MAO-A activity; n=8; (un-
paired two-tailed t test; p=0.06); cQuantitative RT-PCR shows increased
MAO-A and MAO-B expression in CAG180 NPCs when compared to
CAG33 NPCs. Values shown were normalized to CAG33NPCs. CAG33
and CAG180 hiPSCs were described by the HD iPSC Consortium, 2012
[23] and were differentiated into NPCs according to the protocol de-
scribed by Li et al., 2011 [24]; n=3; (unpaired two-tailed t test; p<0.001
for MAO-A mRNA and p=0.007 for MAO-B mRNA). d MAO-A and
MAO-B activities are elevated in CAG180 NPCs. MAO-A and MAO-B
activities were measured using MAO-Glo™ Assay System (Promega).
Values shown were normalized to CAG33 NPCs. CAG33 NPCs
displayed higher activity when compared to CAG33 NPCs. Error bars
in the bar chart represent standard error of the mean, whereas the
whiskers on the box plots represent minimum and maximum values;
n=3-4; (unpaired two-tailed t test; p=0.005 for MAO-A activity and
p=0.006 for MAO-B activity). **p<0.01; ***p<0.001
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tailed t test; p=0.005 for MAO-A activity and p=0.006 for
MAO-B activity).
Discussion
This study demonstrates that MAO-A/B expression and ac-
tivity are elevated in the presence of an expanded
polyglutamine tract in HTT. Increased MAO-A/B activity
plays a role in increasing oxidative stress and increasing
susceptibility to stress-induced impairment in cell viability.
Although oxidative stress is only one contributing factor to
cell death, it is the most pertinent in the context of MAO
isozymes, given their roles in oxidative metabolism.
Elevation of MAO activity was not confined to a cellular
model as a similar trend was observed in HD patient iPSC-
derived neural cells. Overall, this is the first study that looks at
the effect of enhancedMAO activity using biochemical assays
in a well-established striatal and neural cell populations. In
addition, this platform allowed us to evaluate the effects of
pharmacological inhibitors of MAO activity and show that
MAO inhibition alleviated stress-induced impairment in cell
viability in HD mutant cells.
There have been previous reports on the analysis of MAO
expression and activity in HD patients. With the first report in
1978, studies have shown that there is elevated MAO-B
activity in HD patient platelet populations [33–35].
Increased post mortem MAO-B activity in patients suffering
from HD has also been shown [36–38]. It is important to note,
however, that most of these studies were performed before the
causative mutation in HTT was identified. As a result, these
studies did not exclude patients that were HD phenocopies,
and thus were unable to ascertain that the effect is HD-
specific.
In contrast, this study employs genetically defined mouse
and human neural cell populations, highlighting that elevation
of MAO activity is intrinsic to the presence of the mutantHTT
allele. Although a number of studies reported increasedMAO-
B activity in HD patients and cells, one study did not observe
differences in MAO-B activity in platelets among 59 HD
patients, 20 at-risk individuals, 29 control individuals with
an HD family history, and 64 healthy controls [29]. This
discrepancy in reported MAO activity in HD patients may
reflect lack of characterization of the study cohort. Indeed,
lifestyle habits, such as smoking, have been shown to influ-
ence MAO-B activity (reviewed in [5]). As the study cohort
comprised a mixture of HD patients with undefined smoking
habits and receiving various drug interventions, these varia-
tions could have obscured differences in MAO activity. In
general, the findings from previous studies are consistent with
our data where we show that MAO-A/B activity and
expression are increased in human neural cells originating
from HD patients iPSCs.
MAO isozymes play a major role in metabolizing biogenic
and dietary amines, generating hydrogen peroxide as a by-
product. It is conceivable that increased MAO activity in the
presence of mutant HTT results in an accumulation of reactive
oxygen species (ROS). In support of this notion, recent studies
have reported that STHdhQ111/Q111 cells exhibit increased
mitochondrial ROS [30] and addition of a glutathione perox-
idase (GPx) supplement results in the reduction of cell death
[2, 39]. As heightened activity of MAO-A/B leads to an
increase in ROS production, it is possible that MAO acts
upstream of GPx to increase ROS production, thus contribut-
ing to cell death.
Analogous to our findings with MAO inhibitors, a recent
study has demonstrated that knockdown of MAO-A expres-
sion leads to increased ATP levels [40]. MAO-A/B is located
in the outer mitochondrial membrane and their activity leads
to the production of metabolic by-products like H2O2. In HD
mutant cells, increased MAO-A/B activity implicates an ac-
cumulation of ROS. Due to close proximity to the mitochon-
drial oxidative phosphorylation system, it is conceivable that
electron flow through the respiratory chain may be impaired
andATP levelsmay be reduced byROS, possibly contributing
to the lower ATP/ADP ratios seen in HD mutant cells.
Several studies have reported deficits in dopamine levels
and signaling in animal models and patients with HD
(reviewed in [4, 6]). Although this study suggests that in-
creased MAO expression and activity contribute to deficien-
cies in dopamine homeostasis in a HD mutant background, it
is important to note that MAO isozymes metabolize other
substrates. These include serotonin, epinephrine, norepineph-
rine, phenylethylamine, and benzylamine [6, 21]. As there is a
dearth of studies measuring these neurotransmitter levels in
HD, future studies should investigate whether other MAO-
metabolized neurotransmitters are affected in a fashion similar
to dopamine as well as the impact of MAO inhibitors on the
levels of these neurotransmitters.
Despite the unclear link between the presence of mutant
HTT and increased MAO transcriptional activity, there have
been separate lines of evidence that may explain this phenom-
enon. HTT has been shown to regulate Sp1 transcription
factor where mutant HTT forms an enhanced association with
Sp1 [8–10, 41, 42]. As MAO-A/B are both transcriptionally
regulated by Sp1 and Sp3 [10, 11, 21, 22], it is possible that
close interaction between mutant HTT and Sp1 results in
increased MAO expression. Sp1 also affects D2 receptor
expression levels, perhaps perturbing the dopamine metabolic
pathway, and indirectly resulting in increased MAO-A/B
expression.
Although this study delineates the role of increased MAO
activity in a HDmutant background, several questions remain.
The present study was conducted mostly using a striatal cell
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line that carries 111 CAG repeats. The size of the CAG repeat
length inHTT affects the age of onset of motor symptoms and
severity of neuropathology [2, 13–15]; hence, it will be inter-
esting to determine if there is a relationship between the CAG
size and the magnitude of MAO activity. Although we dem-
onstrate that human neural cells derived from HD patient
iPSCs exhibit increased MAO activity, the next step would
be to validate these findings in a larger cohort and to examine
this phenomenon in other tissue types.
In summary, this study provides evidence that cellular HD
models exhibit increased MAO expression and activity,
highlighting the potential of MAO-A/B as pharmacological
targets in HD. MAO-B inhibitors are currently employed in
the clinical setting to treat Parkinsonian symptoms. In addition,
MAO inhibitors have also been shown to possess anti-
depressant properties. As the cardinal features of HD are cog-
nitive, motor, and psychiatric deficits, MAO inhibitors repre-
sent potential candidates for therapeutic intervention in HD.
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